BRAF and breast carcinoma: Based on the data obtained using a panel of breast cancer cell lines and effects seen in patient-derived tumor cells, we also identify the subset of breast cancers that will be resistant to treatment, that is TNBCs with KRAS or BRAF mutations, or TNBCs with high MAPK activity.